16.09
-1.95%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangzhou Wondfo Biotech Co
Its shares trade on Shenzhen under the ticker 300482.SZ. It has been listed since 30 June 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.09bn and a net loss of CN¥63.0m. At that date it held total assets of CN¥6.60bn and shareholders' equity of CN¥5.41bn.
Guangzhou Wondfo Biotech Co., Ltd. engages in the manufacture and sale of biochemical reagents, medical products and diagnostic test kits. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2015-06-30. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The firm's products are used in POCT, clinical test, field test and personal health management, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 30 Jun 2015
- Employees
- 3,459
- Website
- wondfo.com/index ↗
Leadership
Pay as last reported
- Ms. Jihua WangChairman of the Board, since 2015CN¥1.7m
- Ms. Fangxia YuChief Financial Officer, Deputy General ManagerCN¥1.8m
- Mr. Zhongxiong PengGeneral Manager, DirectorCN¥1.6m
- Mr. Yaping ZhaoDeputy General Manager, Director, since 2018CN¥1.4m
- Ms. Keren KangDeputy General ManagerCN¥1.0m
- Ms. Hong HuSecretary of the BoardCN¥924,700
- Mr. Dali LiDirectorCN¥1.4m
- Mr. Chaohui DuanIndependent Director
- Mr. Congdong LiIndependent DirectorCN¥80,000
- Mr. Wenjin OuyangIndependent DirectorCN¥43,700
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 29
- Environment
- 18
- Social
- 26
- Governance
- 42
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Guangzhou Wondfo Biotech employs 3459 employees in Guangzhou, China.
- Guangzhou Wondfo Biotech offers diagnostic test kits for pregnancy and infectious diseases.
- Guangzhou Wondfo Biotech's products are used in POCT, clinical, and field testing.
Weaknesses
- Guangzhou Wondfo Biotech's IPO was on 30 June 2015, a late entry to the market.
- Guangzhou Wondfo Biotech's products are limited to qualitative and quantitative testing.
- Guangzhou Wondfo Biotech's headquarters is in Guangzhou, China, a single location.
Opportunities
- Guangzhou Wondfo Biotech can expand into chronic disease testing series for growth.
- Guangzhou Wondfo Biotech can target the growing POCT market in China.
- Guangzhou Wondfo Biotech can leverage its 3459 employees for innovation.
Threats
- Guangzhou Wondfo Biotech faces competition from other Health Care companies in China.
- Guangzhou Wondfo Biotech's reliance on China's market limits global expansion.
- Guangzhou Wondfo Biotech's products are restricted to specific testing categories.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.